The anti-tumor effects of an anti-cd71 chimeric antibody in vitro and its distribution in a tumor xenograft model

Chinese-German Journal of Clinical Oncology

Volumn 1, Issue 2, 2002, Pages 109-112

  Yang, Daofeng ^a   Wang, Shuo ^b   Zhu, Ituifcn ^c   Shen, Guanxin ^c  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b JIANGHAN UNIVERSITY   (China)

^c Tongji mtxlie'Al College   (China)

Author keywords

AIX'C; CD71; CI) c; Human mm'ine chimeric antibody

Indexed keywords

EID: 22144495160     PISSN: 16101979     EISSN: 16139089     Source Type: Journal    
DOI: 10.1007/BF02851748     Document Type: Article

References (8)

1. Crillo-Lopez A J, White CA, Vams C, et al. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin Oncol, 1999, 26(5 Suppl 14):66-73.
2. Goldenherg MM. Trastuzumab, a recombinant DNA-derived humanized monoelonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther, 1999, 21(2): 309-318.
3. Thorson JA, Smith KM, Gomez F, et ai. Role of iron in T cell activation: TH1 clones differ from TH2 elones in their sensitivity to inhibition of DNA synthesis caused by IgG Mabs against the transferrin receptor and the iron chelator deferoxamine. Cell Immunol, 1991, 134(1):126-137.
4. Kemp JD. Iron deprivation and cancer: a view beginning with studies of monoclonal antibodies against the transfenin receptor. Histol Histopathol, 1997, 12(1 ) :291-296.
5. Kovar J, Stunz LL, Stewart BC, et al. Direct evidence that iron deprivation induces apoptosis in murine lymphoma 38C13. Pathobiology, 1997, 65(2): 61-68.
6. . Weiner LM. An overview of monoclonal antibody therapy of cancer. Semin Oncol, 1999, 26(4 Suppl 12) :41-50.
7. Vandevyver C, Steukers M, Laznhreehts J, et al. Development and functional characterization of a murine/hurnan chimeric antibody with specificity for the human intedeukin=2 receptor. Mol Immanol, 1993, 30(10) : 865-876.
8. Sahagan BG, Dorai H, Sahzgaber-Muller J, et al. A genetically engineered murine/hmnan chimeric antibody retains specificity for hanan tumor-associated antigen. J hnmunol, 1986, 137(3) : 1066-1074.